244 related articles for article (PubMed ID: 1526645)
21. Proteomic analysis of anti-Francisella tularensis LVS antibody response in murine model of tularemia.
Havlasová J; Hernychová L; Brychta M; Hubálek M; Lenco J; Larsson P; Lundqvist M; Forsman M; Krocová Z; Stulík J; Macela A
Proteomics; 2005 May; 5(8):2090-103. PubMed ID: 15892173
[TBL] [Abstract][Full Text] [Related]
22. Signatures of T cells as correlates of immunity to Francisella tularensis.
Eneslätt K; Normark M; Björk R; Rietz C; Zingmark C; Wolfraim LA; Stöven S; Sjöstedt A
PLoS One; 2012; 7(3):e32367. PubMed ID: 22412866
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease.
Green M; Choules G; Rogers D; Titball RW
Vaccine; 2005 Apr; 23(20):2680-6. PubMed ID: 15780452
[TBL] [Abstract][Full Text] [Related]
24. Persistence of cell-mediated immunity and decline of humoral immunity to the intracellular bacterium Francisella tularensis 25 years after natural infection.
Ericsson M; Sandström G; Sjöstedt A; Tärnvik A
J Infect Dis; 1994 Jul; 170(1):110-4. PubMed ID: 8014484
[TBL] [Abstract][Full Text] [Related]
25. Immunodominant Francisella tularensis antigens identified using proteome microarray.
Eyles JE; Unal B; Hartley MG; Newstead SL; Flick-Smith H; Prior JL; Oyston PC; Randall A; Mu Y; Hirst S; Molina DM; Davies DH; Milne T; Griffin KF; Baldi P; Titball RW; Felgner PL
Proteomics; 2007 Jun; 7(13):2172-83. PubMed ID: 17533643
[TBL] [Abstract][Full Text] [Related]
26. [Tularemia, "volume" two].
Macela A
Epidemiol Mikrobiol Imunol; 1998 Aug; 47(3):103-20. PubMed ID: 9748768
[TBL] [Abstract][Full Text] [Related]
27. Francisella tularensis vaccines.
Griffin KF; Oyston PC; Titball RW
FEMS Immunol Med Microbiol; 2007 Apr; 49(3):315-23. PubMed ID: 17316369
[TBL] [Abstract][Full Text] [Related]
28. Th17 cytokines in recall responses against Francisella tularensis in humans.
Paranavitana C; Zelazowska E; DaSilva L; Pittman PR; Nikolich M
J Interferon Cytokine Res; 2010 Jul; 30(7):471-6. PubMed ID: 20626289
[TBL] [Abstract][Full Text] [Related]
29. Development of Francisella tularensis antigen responses measured as T-lymphocyte proliferation and cytokine production (tumor necrosis factor alpha, gamma interferon, and interleukin-2 and -4) during human tularemia.
Surcel HM; Syrjälä H; Karttunen R; Tapaninaho S; Herva E
Infect Immun; 1991 Jun; 59(6):1948-53. PubMed ID: 1674737
[TBL] [Abstract][Full Text] [Related]
30. [Cross immunity to plague and tularemia].
Vasenin AS; Veĭnblat VI; Samoĭlova LV
Zh Mikrobiol Epidemiol Immunobiol; 1980; (2):49-52. PubMed ID: 7395403
[No Abstract] [Full Text] [Related]
31. Orchestration of the protective immune response to intracellular bacteria: Francisella tularensis as a model organism.
Tärnvik A; Ericsson M; Golovliov I; Sandström G; Sjöstedt A
FEMS Immunol Med Microbiol; 1996 Mar; 13(3):221-5. PubMed ID: 8861033
[TBL] [Abstract][Full Text] [Related]
32. Natural killer and CD8 T cells dominate the response by human peripheral blood mononuclear cells to inactivated Francisella tularensis live vaccine strain.
Gosselin EJ; Gosselin DR; Lotz SA
Hum Immunol; 2005 Oct; 66(10):1039-49. PubMed ID: 16386645
[TBL] [Abstract][Full Text] [Related]
33. Nucleotide sequence and T cell epitopes of a membrane protein of Francisella tularensis.
Sjöstedt A; Sandström G; Tärnvik A; Jaurin B
J Immunol; 1990 Jul; 145(1):311-7. PubMed ID: 1694206
[TBL] [Abstract][Full Text] [Related]
34. Tularaemia in the rat. I. The cellular basis on host resistance to infection.
Kostiala AA; McGregor DD; Logie PS
Immunology; 1975 May; 28(5):855-69. PubMed ID: 236983
[TBL] [Abstract][Full Text] [Related]
35. The tularaemia vaccine.
Sandström G
J Chem Technol Biotechnol; 1994 Apr; 59(4):315-20. PubMed ID: 7764815
[TBL] [Abstract][Full Text] [Related]
36. Tularemia vaccines.
Putzova D; Senitkova I; Stulik J
Folia Microbiol (Praha); 2016 Nov; 61(6):495-504. PubMed ID: 27194547
[TBL] [Abstract][Full Text] [Related]
37. Francisella tularensis-induced in vitro gamma interferon, tumor necrosis factor alpha, and interleukin 2 responses appear within 2 weeks of tularemia vaccination in human beings.
Karttunen R; Surcel HM; Andersson G; Ekre HP; Herva E
J Clin Microbiol; 1991 Apr; 29(4):753-6. PubMed ID: 1909711
[TBL] [Abstract][Full Text] [Related]
38. [Evaluation of immunobiological activity of Francisella tularensis C-complex preparations as promising component of subunit vaccines].
Volokh OA; Shepelev IA; Firsova VV; Khramkova EM; Avdeeva NG; Samokhvalova IuI; Eremin SA; Diatlov IA; Zhemchugov VE
Zh Mikrobiol Epidemiol Immunobiol; 2007; (3):16-21. PubMed ID: 17672125
[TBL] [Abstract][Full Text] [Related]
39. An in vitro model system used to study adherence and invasion of Francisella tularensis live vaccine strain in nonphagocytic cells.
Lindemann SR; McLendon MK; Apicella MA; Jones BD
Infect Immun; 2007 Jun; 75(6):3178-82. PubMed ID: 17339345
[TBL] [Abstract][Full Text] [Related]
40. Cell-mediated immunity against Francisella tularensis after natural infection.
Koskela P; Herva E
Scand J Infect Dis; 1980; 12(4):281-7. PubMed ID: 7006062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
